Investor

Downloads


Executive Summary

Genprex (NASDAQ : GNPX) is a clinical-stage biopharmaceutical company developing novel gene therapies to improve outcomes for cancer patients receiving promising targeted and immunotherapies, as well as to expand therapeutic benefits to a greater number of patients. The Company’s unique approach to cancer treatment is…

Download

Investor Presentation

This presentation may contain projections or other forward-looking statements regarding future events, the safety and efficacy of our product candidates, or the future financial performance of our company. These forward-looking statements may contain forward-looking words such as “may,” “might,” “should,”…

Download

AACR 2019 Hu-PDX Poster

Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer

Download

2017 AACR Poster

TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural…

Download

2012 AACR Poster – Yan

DNA alkylating agents such as platinum and nitrogen mustard are effective cancer chemotherapeutics. They kill proliferating tumor cells by inducing high levels of DNA damage leading to cell-cycle arrest and cell death. However, their highly toxic side effects and the common drug resistance exhibited in tumors limit their…

Download

2012 AACR Poster – Meng

TUSC2, a novel tumor suppressor gene in the human chromosome 3p21.3 region, is deleted in many cancers. A phase I clinical trial assessing TUSC2-mediated molecular therapy has reported antitumor activity in lung cancer patients. Previous studies showed that TUSC2 regulates the activation of multiple oncogenic kinases…

Download

2011 AACR Poster

A poster describing a phase I clinical trial investigating Oncoprex® (intravenous TUSC2 nanovesicles) used a single agent in recurrent, metastatic lung cancer patients. The dose escalation clinical trial was conducted at The University of Texas MD Anderson Cancer Center. The poster was presented at the 2011 Annual Meeting of…

Download

2011 AACR Abstract

An abstract describing a phase I clinical trial investigating Oncoprex® (intravenous TUSC2 nanovesicles) used a single agent in recurrent, metastatic lung cancer patients. The dose escalation clinical trial was conducted at The University of Texas MD Anderson Cancer Center. The abstract was published in the Proceedings of…

Download

Bibliography

A bibliography of selected publications describing technologies from Genprex.

Download

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link